Stephens downgraded Elevance Health from Overweight to Equal-Weight and set a new price target of $440.00 from $520.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | Neutral | Goldman | |
| 7/21/2025 | Buy → Hold | Argus | |
| 7/18/2025 | $310.00 | Outperform → Market Perform | Leerink Partners |
| 4/15/2025 | $529.00 | Outperform → Neutral | Robert W. Baird |
| 3/17/2025 | $450.00 | Hold → Buy | Argus |
| 1/22/2025 | $520.00 → $440.00 | Overweight → Equal-Weight | Stephens |
| 10/18/2024 | Buy → Hold | Argus | |
| 7/18/2024 | $646.00 → $530.00 | Buy → Neutral | BofA Securities |
Goldman initiated coverage of Elevance Health with a rating of Neutral
Argus downgraded Elevance Health from Buy to Hold
Leerink Partners downgraded Elevance Health from Outperform to Market Perform and set a new price target of $310.00
By simplifying the healthcare experience, improving care coordination, and leveraging data-driven insights, Elevance Health affiliated health plans help members navigate a range of healthcare experiences with greater confidence As 2025 draws to a close, Elevance Health highlights how today's health plans are evolving to better support their members in a broader range of situations that affect health, including cancer diagnoses, mental health crises, and unexpected health concerns during pregnancy. From employer-sponsored health insurance to government-sponsored programs, health plans are evolving to better support their members in a broader range of situations that affect health. In partne
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+" (Excellent) from "a-" (Excellent) of Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+"
The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an
8-K - Elevance Health, Inc. (0001156039) (Filer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
10-Q - Elevance Health, Inc. (0001156039) (Filer)
3/A - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
The board of directors of Elevance Health (NYSE:ELV) today announced the appointment of Amy Schulman, a recognized healthcare executive, investor, and governance leader, as an independent director, effective January 12, 2026. Schulman will serve on the Audit and Finance Committees, contributing deep expertise in healthcare innovation, regulatory strategy, and value creation across complex, global enterprises. This appointment reflects Elevance Health's ongoing board refreshment strategy to ensure diverse, independent, and future-focused leadership that aligns with the company's long-term strategy and stakeholders' priorities. "Amy's record of driving innovation, disciplined investment, an
Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe
Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+" (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) (NYSE:ELV), as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+" (Excellent) from "a-" (Excellent) of Wellpoint Life and Health Insurance Company and Wellpoint West Virginia, Inc. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of "bbb+"
Executing with discipline to improve affordability and elevate the member experience 3Q 2025 operating revenue of $50.1 billion, up 12.0% from 3Q 2024 3Q 2025 diluted EPS1 of $5.32; adjusted diluted EPS2 of $6.03 Reaffirm FY 2025 benefit expense ratio and adjusted diluted EPS guidance of approximately 90.0% and approximately $30.00, respectively Returned $3.3 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported third quarter 2025 results. "Our third quarter results were in line with expectations and reflect disciplined execution across Elevance Health. In a dynamic healthcare environment, we're focused on advancing affordability and ele
Elevance Health (NYSE: ELV) will release third quarter 2025 financial results on October 21, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 21, 2025, until the end of the day on November 21, 2025. Th